AKRO Akero Therapeutics
- 21.070
- +0.770+3.79%
Akero Therapeutics News
Evercore ISI Group: Maintaining the Akero Therapeutics (AKRO.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $50.00 to $38.00.
Akero Therapeutics Analyst Ratings
Evercore ISI Group Maintains Outperform on Akero Therapeutics, Lowers Price Target to $38
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Akero Therapeutics (AKRO) and Madrigal Pharmaceuticals (MDGL)
HC Wainwright & Co. : The Akero Therapeutics (AKRO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $50.00.
Akero Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $50 Price Target
Positive Buy Rating for Akero Therapeutics Backed by Clinical and Operational Progress
B of A Securities: Reiterates Akero Therapeutics' (AKRO.US) neutral rating with a target price of $30.00.
Akero Therapeutics Analyst Ratings
Akero Therapeutics' Strong Trial Results and Market Positioning Justify Buy Rating
Akero Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO)
Akero Therapeutics: Promising Phase IIb Results Propel Strong Buy Rating
HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $43
Akero Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Akero Therapeutics (AKRO)
Akero Therapeutics' Buy Rating Affirmed on Efruxifermin's Promise for NASH Treatment
Akero Therapeutics' Progress in Metabolic Liver Disease Treatments Prompts Buy Rating
Akero Therapeutics: Promising Results and Buy Rating Based on Efruxifermin's Potential in NASH Treatment
Analysis
Price Target
No Data
